Combating Progressive Disease by Monitoring and Early Detection: War and PCR

Radich, MD



Combating Progressive Disease by Monitoring and Early Detection: War and PCR
What I am going to talk about today, as mentioned, is how we can use molecular biology to really start to tailor treatment for chronic myelogenous leukemia (CML).

Now, CML is not a public health menace. The incidence is approximately 2 per 100,000, but it has really taught us probably more about cancer and diagnostics than any other solid or liquid tumor out there, not only the advent of imatinib and the other agents of targeted therapy but also the use of molecular biology to really understand how to alter therapy, to understand the basic biology of therapy. What I am going to talk today about is residual disease monitoring and its importance and also talk a little bit about the molecular biology and treatment of blast crisis.

.... read full article here